Profile data is unavailable for this security.
About the company
Chengdu Olymvax Biopharmaceuticals Inc is a China-based biopharmaceutical company mainly engaged in the research, development, production and sales of human vaccines. The Company's products mainly include adsorbed tetanus vaccine, Hib conjugate vaccine and tetanus toxoid concentrate stock solution. The Company's main customers are center for disease control and prevention (CDC) customers.
- Revenue in CNY (TTM)709.13m
- Net income in CNY64.21m
- Incorporated2009
- Employees470.00
- LocationChengdu Olymvax Biopharmaceuticals IncNo. 99 Tianxin Road, High-tech ZoneCHENGDU 611731ChinaCHN
- Phone+86 2 869361198
- Fax+86 2 869361100
- Websitehttps://www.olymvax.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chongqing Genrix Biophrmctcl Co Ltd | 225.16m | -583.52m | 10.41bn | 743.00 | -- | 5.82 | -- | 46.22 | -1.59 | -1.59 | 0.6141 | 4.88 | 0.0712 | 0.3088 | 10.33 | 303,044.90 | -18.45 | -- | -19.95 | -- | 90.99 | -- | -259.16 | -- | 7.37 | -- | 0.3694 | -- | 2,384.11 | -- | 0.5049 | -- | -- | -- |
| Liaoning Chengda Biotechnology Co Ltd | 1.47bn | 177.94m | 10.67bn | 1.81k | 59.19 | 1.14 | -- | 7.26 | 0.433 | 0.433 | 3.56 | 22.54 | 0.1482 | 0.6786 | 1.24 | 813,192.10 | 1.79 | 8.07 | 1.86 | 8.36 | 79.03 | 84.98 | 12.11 | 35.75 | 19.28 | -- | 0.0013 | 44.77 | -4.22 | -0.0082 | -26.42 | -13.26 | -4.72 | -- |
| Jiangsu Sinopep Allsin Bphrmctcl Co Ltd | 1.90bn | 498.69m | 10.68bn | 2.03k | 21.17 | 3.43 | -- | 5.62 | 1.60 | 1.60 | 6.13 | 9.84 | 0.3413 | 0.9306 | 3.06 | 936,748.90 | 8.90 | 7.19 | 13.04 | 9.67 | 66.64 | 59.30 | 26.08 | 20.28 | 0.928 | 16.07 | 0.4604 | 35.89 | 57.21 | 34.33 | 148.19 | 52.76 | 31.58 | -- |
| Aurisco Pharmaceutical Co Ltd | 1.62bn | 424.54m | 10.78bn | 1.78k | 25.08 | 4.24 | -- | 6.63 | 1.06 | 1.06 | 4.07 | 6.26 | 0.4188 | 1.09 | 4.41 | 910,578.10 | 10.94 | 11.37 | 12.60 | 13.29 | 59.77 | 52.93 | 26.13 | 22.34 | 3.01 | 635.15 | 0.2806 | 31.53 | 16.89 | 20.47 | 22.59 | 13.77 | 49.45 | -- |
| Chengdu Olymvax Biopharmaceuticals Inc | 709.13m | 64.21m | 11.01bn | 470.00 | 170.94 | 11.47 | -- | 15.52 | 0.1587 | 0.1587 | 1.75 | 2.36 | 0.3883 | 0.654 | 1.19 | 1,508,792.00 | 3.45 | 3.25 | 5.00 | 4.81 | 92.66 | 93.62 | 8.88 | 8.11 | 1.42 | 8.30 | 0.2906 | 7.39 | 18.69 | 26.88 | 18.24 | -- | 48.00 | -- |
| Shanghai Yizhong Pharmaceutical Co Ltd | 247.05m | 22.96m | 11.02bn | 65.00 | 471.02 | 7.54 | -- | 44.60 | 0.1132 | 0.1132 | 1.22 | 7.07 | 0.163 | 0.9556 | 2.26 | 3,800,801.00 | 1.51 | 5.44 | 1.58 | 5.64 | 81.39 | 92.99 | 9.30 | 36.90 | 7.84 | -- | 0.00 | 32.30 | -51.83 | -- | -95.68 | -- | 10.96 | -- |
| Cansino Biologics Inc | 971.83m | -142.03m | 11.23bn | 1.11k | -- | 2.99 | -- | 11.55 | -0.5455 | -0.5455 | 3.92 | 21.37 | 0.1271 | 0.5861 | 1.38 | 879,482.50 | -1.86 | -4.08 | -2.29 | -5.38 | 78.80 | 45.31 | -14.62 | -27.51 | 3.29 | -- | 0.2242 | -- | 137.01 | 226.43 | 74.45 | -- | 31.38 | -- |
| Zhejiang CONBA Pharmaceutical Co., Ltd. | 6.58bn | 687.99m | 11.23bn | 8.26k | 16.62 | 1.58 | -- | 1.71 | 0.2665 | 0.2665 | 2.54 | 2.80 | 0.6617 | 2.57 | 4.70 | 796,529.00 | 7.13 | 8.51 | 9.65 | 12.74 | 51.88 | 58.64 | 10.77 | 14.12 | 1.38 | -- | 0.0532 | 41.54 | -3.23 | -0.7594 | 5.21 | -- | 1.57 | -- |
| Chengdu Easton Biopharmaceuticals Co Ltd | 1.33bn | 241.37m | 11.37bn | 1.52k | 46.91 | 3.97 | -- | 8.55 | 1.37 | 1.37 | 7.55 | 16.23 | 0.3809 | 1.83 | 5.89 | 873,161.50 | 6.92 | 8.09 | 8.44 | 9.82 | 71.90 | 81.72 | 18.16 | 20.10 | 3.12 | -- | 0.0444 | 30.37 | 20.82 | 7.34 | 5.15 | 17.01 | 4.24 | -- |
| Mayinglong Pharmaceutical Group Co Ltd | 3.77bn | 571.60m | 11.66bn | 2.65k | 20.39 | 2.71 | -- | 3.09 | 1.33 | 1.33 | 8.75 | 9.97 | 0.7211 | 6.23 | 11.99 | 1,421,812.00 | 11.38 | 10.77 | 13.82 | 13.35 | 46.77 | 42.40 | 15.78 | 14.39 | 4.58 | -- | 0.0226 | 37.31 | 18.85 | 6.62 | 19.14 | 7.97 | 34.47 | 18.98 |
| Jiangxi Tianxin Pharmaceutical Co Ltd | 2.23bn | 617.04m | 11.82bn | 2.68k | 19.07 | 2.47 | -- | 5.31 | 1.42 | 1.42 | 5.11 | 10.93 | 0.3973 | 2.43 | 9.65 | 830,883.10 | 11.01 | 17.10 | 11.88 | 21.16 | 43.04 | 42.99 | 27.72 | 30.12 | 4.31 | -- | 0.0721 | 24.41 | 17.35 | 1.75 | 36.85 | -2.20 | 35.06 | -- |
Data as of Feb 13 2026. Currency figures normalised to Chengdu Olymvax Biopharmaceuticals Inc's reporting currency: Chinese Yuan Renminbi CNY
16.63%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Aegon-Industrial Fund Management Co., Ltd.as of 30 Jun 2025 | 38.96m | 13.52% |
| E Fund Management Co., Ltd.as of 30 Jun 2025 | 2.67m | 0.93% |
| Fullgoal Fund Management Co., Ltd.as of 30 Jun 2025 | 2.30m | 0.80% |
| China Southern Asset Management Co., Ltd.as of 30 Jun 2025 | 997.94k | 0.35% |
| Bosera Asset Management Co., Ltd.as of 30 Jun 2025 | 728.20k | 0.25% |
| ABC-CA Fund Management Co., Ltd.as of 30 Jun 2025 | 689.54k | 0.24% |
| Cinda Fund Management Co. Ltd.as of 30 Jun 2025 | 684.19k | 0.24% |
| China International Capital Corp. HK Asset Management Ltd.as of 30 Jun 2025 | 555.40k | 0.19% |
| Penghua Fund Management Co., Ltd.as of 30 Jun 2025 | 181.13k | 0.06% |
| GF Fund Management Co., Ltd.as of 30 Jun 2025 | 178.34k | 0.06% |
More ▼
Data from 30 Jun 2025 - 12 Feb 2026Source: FactSet Research Systems Inc.
